{"slug":"tesamorelin-tendon","verification":{"valid":true,"entries":2,"head":"3dd34b26e7cd117fda97623cbd8e4c57abfe57698f8ba4b8915e86335b780d17"},"energy":{"passes":2,"tokens_in":14338,"tokens_out":2764,"tokens_total":17102,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"3dd34b26e7cd117fda97623cbd8e4c57abfe57698f8ba4b8915e86335b780d17"},"provenance":[{"ts":"2026-06-29T23:11:59.566Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Tendon\nSlug: tesamorelin-tendon\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down\",\"Why Tesamorelin might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.","response":"{\"slug\":\"tesamorelin-tendon\",\"title\":\"Tesamorelin for Tendon Repair: Evidence Review\",\"body\":\"## What's breaking down\\nTendon problems often trace to layers where breakdown outruns repair. Collagen fibers in the tendon matrix lose alignment and strength. Tenocytes, the cells that maintain the matrix, slow their output of new collagen type I. Blood supply stays limited, so nutrients and repair signals reach the site slowly. Inflammation can linger or shift into a state that favors scar tissue over organized repair. Over time these layers compound: weaker matrix leads to micro-tears, which trigger more inflammation and further slow cell activity. The result is persistent pain or reduced function rather than full restoration.\\n\\n## Why Tesamorelin might help you\\nTesamorelin acts on the GH axis. It stimulates the pituitary to release more growth hormone. Growth hormone in turn raises IGF-1. Both GH and IGF-1 have been linked to collagen production in connective tissue.\\n\\nIf your tendon issue involves slowed collagen synthesis, the chain runs like this: Tesamorelin raises GH → GH reaches tendon fibroblasts → collagen synthesis markers increase. A 2009 human study gave GH to healthy adults and measured collagen synthesis directly in tendon tissue via stable isotope methods. Collagen synthesis rose significantly while muscle myofibrillar protein synthesis did not. That points to a selective effect on the extracellular matrix rather than bulk muscle growth.\\n\\nIf visceral fat or systemic metabolic load is part of your picture, Tesamorelin’s primary approved use (visceral fat reduction in HIV lipodystrophy) could matter indirectly. Less central fat sometimes correlates with lower systemic inflammation, which might ease one degenerative layer. The trial data on nerve injury recovery also lists possible secondary effects on tendon healing, though these remain hypotheses tied to the same GH/IGF-1 pathway.\\n\\nThe framing stays repair-oriented: the discussion centers on whether","tokens_in":14338,"tokens_out":2764,"cost":0,"prev":"genesis","hash":"526fd7b55c41a91225af1d26e825afd8b7ee1a00c06b09baf488d1629300e8df"},{"ts":"2026-07-17T02:42:27.625Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-tendon","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"526fd7b55c41a91225af1d26e825afd8b7ee1a00c06b09baf488d1629300e8df","hash":"3dd34b26e7cd117fda97623cbd8e4c57abfe57698f8ba4b8915e86335b780d17"}]}